Download as pdf or txt
Download as pdf or txt
You are on page 1of 44

Start-up Village

@EFIB 2019

30 Sep–2 Oct 2019


Brussels · Belgium

#EFIB2019

Organised by Supporting Partner Local Partner


About the Start-up Village @EFIB

The START-UP VILLAGE@EFIB is a central meeting point in the exhibition area, bringing
together innovative young businesses with investors as well as industrial corporations.
It offers 30 founders who are active in industrial biotechnology and bioeconomy strong
visibility among the international 500+ EFIB attendees, representing sector stakeholders
from companies, academics, SMEs, investors, policy makers, NGOs and media.

The Start-up Village represents companies from the following areas:

Bio-based Food & Textiles Cosmetics Agriculture Bio-based


Chemicals Nutrition & Forestry Materials

WE THANK OUR PARTNERS


Content

Networking Partners
Toulouse White Biotechnology ................ 5 IAR ............................................................. 6
G-BIB .......................................................... 5 Technologieland Hessen .......................... 7
DSM ........................................................... 6 Capricorn Venture Partners ...................... 7

Start-up Profiles
Abolis Biotechnologies ........................... 11 Innovived VZW .........................................26
aquila biolabs GmbH ............................. 12 Kapsera SAS .............................................27
BGene ...................................................... 13 Knufmann GmbH .....................................28
Bialtec SAS .............................................. 14 LignoPure GbR .........................................29
Bicomer ................................................... 15 madebymade GmbH ................................30
Cellulosic Technologies UG ................... 16 MilliDrop....................................................31
Chrysalix Technologies Ltd .................... 17 Native Foods-Carrillo Wilisch-Kreßner-GbR .32
dieWurmfarm ......................................... 18 NEFFA .......................................................33
EBS – Engineering BioSurfactants ........ 19 Rebel Meat GmbH ....................................34
Evonetix Ltd ............................................ 20 Roquette Klötze GmbH & Co. KG ............35
FGen GmbH ..............................................21 ScobyTec ..................................................36
Fornia BioSolutions Inc. ...........................22 Senbis Polymer Innovations B.V. ............37
Green Rose Chemistry .............................23 Syngulon SA .............................................38
Higher Steaks ...........................................24 Vienna Textile Lab....................................39
Indianes ....................................................25 Whapow Deutschland GmbH ..................40
Networking Partners
Toulouse White Biotechnology
General aim of the consortium
TWB helps industry in facing climate change along its corporate social responsibility: TWB de-
velops innovative and sustainable routes from renewable feedstocks to produce, using the liv-
ing, existing products and new ones with novel performances. Supported by a consortium of 50
partners (inc. 34 industrials), TWB uses its technology platforms to accelerate product develop-
ment for private companies. Partnering with leading-edge public laboratories, TWB leverages
their state-of-the-art expertise and capabilities to develop biotechnology-based processes. Its
activities ranges from catalyst development (enzyme and microorganisms) to setting-up pre-
industrial process. TWB is also supporting start-up development. It currently hosts 6 start-up
and provides technical, scientific and administrative assistance so that they can demonstrate
their proof of concept. TWB projects are led with an ethics and sustainability approach.

Profile of partners involved


The TWB consortium currently includes 34 companies (from start-up to large company, involved
in various field of applications, product or process developers and technology providers), 4 in-
vestors, 3 tech transfer partners and 9 public partners including the 3 administrative bodies of
TWB (INRA, INSA, CNRS).

CONTACT

Laurie Rey
Director, Business · laurie.rey@inra.fr

G-BiB
General aim of the consortium
The G-BiB is an international student competition aiming at stimulating entrepreneurship and
innovation. Teams can register with an idea for a sustainable product or production. During the
competition they will get trained and supported in writing their business plan and pitching their
case. In national semifinals and an international final expert juries chose the best idea to be
awarded. In 2019 the competition was held in Germany and Belgium and was hosted by CLIB,
Bio Base Europe Pilot Plant and Flanders Biobased Valley. The final award was a free sparring
day at the High-Tech Gruenderfonds and 7,500 € prize money sponsored by Henkel.

CONTACT

Katrin Kriebs
Project Manager · kriebs@clib-cluster.de

5
DSM and Biotech Campus Delft
Biotech Campus Delft: an open innovation ecosystem
that enables the transition to a bio-based economy
Royal DSM, a global purpose-led, science-based company active in Nutrition, Health and Sustain-
able Living, recently founded the Biotech Campus Delft, in close collaboration with Delft University
of Technology and regional partners, to accelerate collaborations between biotechnology compa-
nies and knowledge institutes. This ground-breaking campus in the Netherlands hosts startups,
tech- and service-providers, small and medium-sized enterprises and established companies in
the field of biotechnology and creates an ecosystem that boosts the transition to a sustainable,
bio-based and circular economy. The open innovation campus supports the whole innovation
cycle, from research to piloting, and through scale-up to production and commercialization. Ex-
amples of recent innovations developed at the Biotech Campus Delft are Veramaris’ algae-de-
rived Omega-3 oil, enabling more sustainable aquaculture and healthier fish for the consumer, and
Avansya’s zero-calorie sweetener. www.biotechcampusdelft.com
This year, DSM celebrates 150 years of fermentation and biotechnology expertise and innovation at
its site in Delft, the Netherlands. Today’s biotechnology competences and expertise rank DSM among
the top companies in the world in industrial biotechnology. DSM believes that biotechnology based
solutions will be key to address some of the world’s biggest challenges, including climate change,
resource scarcity, circularity and enabling healthy nutrition for a fast-growing global population.

CONTACT

Cindy Gerhard
Business Development Director · Cindy.Gerhardt@dsm.com · +31 (0) 6 13 21 04 79

IAR
IAR is the leading Bioeconomy Cluster, recognised across Europe and internationally. It gathers
400 members from across the entire bio-based value chain, from upstream agricultural inputs to
the marketing of finished products. Members include agricultural coopératives, research institu-
tions and universities, companies of all sizes, public stakeholders…
The IAR Cluster works on all topics related to the production and optimal use of biological re-
sources (agriculture, forestry, marine resources or by-products and residues) for food, industrial
and energy purposes. Since 2005, IAR has supported 300 projects worth €1,7 billion. IAR has a
broad membership of active and innovative stakeholders from accross the entire bio-based value
chain. By offering tailored support, IAR Cluster services are designed to improve your competitive-
ness through innovation!
CONTACT

Johan De Coninck
Networks & Enterprises Development Director · deconinck@iar-pole.com

6
Technologieland Hessen
Under the brand “Technologieland Hessen” Hessen Trade & Invest offers networking, advise and
information for future-oriented companies throughout Hessen. On behalf of Hessen’s Ministry of
Economics, Energy, Transport and Housing, we support the development, application and market-
ing of key technologies on a holistic, neutral, open and free-of-charge basis. In order to keep pace
with current technological and social developments, it is important both to have an eye on individ-
ual technologies and to identify synergies. Thereby, we map the state’s various key technologies in
specialist fields of technology. In the technology field Life Sciences & Bioeconomics, we support
the transition to a biobased economy that is both economically and ecologically sustainable. Our
experts’ aim is to advance technologies and thus strengthen the position of your company.

CONTACT

Janin Sameith
Director Life Sciences & Bioeconomy · Janin.Sameith@htai.de

Capricorn Partners
Capricorn Partners is an independent European manager of venture capital and equity funds,
investing in innovative companies with technology as competitive advantage. The investment
team of Capricorn is composed of experienced investment managers with deep technology
expertise and a broad industrial experience. Capricorn Partners is investing out of the private
venture capital funds Capricorn Digital Growth Fund, Capricorn Sustainable Chemistry Fund,
Capricorn ICT Arkiv Fund, Capricorn Health-tech Fund and Capricorn Cleantech Fund. In ad-
dition, Capricorn Partners, in a joint venture with the China based Capricorn Scorpio Invest-
ment Management, acts as the exclusive investment advisor of the China – Belgium (Europe)
Technology Innovative Industry Fund. Capricorn Partners is also the management company of
Quest for Growth, quoted on NYSE Euronext Brussels, and the investment manager of Quest
Cleantech Fund and Quest+, sub-funds of Quest Management SICAV. (www.capricorn.be)

Investment focus: We focus on companies with technology as competitive advantage in


strategic areas of ICT, Healthtech and Cleantech. Capricorn aims to acquire significant mi-
nority stakes in start- and scale-ups. Its Capricorn Sustainable Chemistry Fund invests in
firms that answer to the need for novel feedstock, innovative & sustainable chemical pro-
cesses, better functional materials, food & feed products, fibres and jet fuels.

CONTACT

Jos B. Peeters
Chairman Executive Committee · jos@capricorn.be

7
Start-up Village

1 4 1 4

A C
2 3 2 3

1 1 1

B D E
2 3 2 3 2

A C
Rebel Meat GmbH ......................... A1 Higher Steaks ................................ C1
Native Foods ................................ A2 Bialtec SAS .................................... C2
dieWurmfarm ................................ A3 Kapsera SAS .................................. C3
madebymade GmbH ..................... A4 Bicomer .......................................... C4

B D
Knufmann GmbH .......................... B1 Green Rose Chemistry .................. D1
Roquette Klötze GmbH & Co. KG . B2 MilliDrop ......................................... D2
Whapow Deutschland GmbH ....... B3 aquila biolabs GmbH .................... D3

E
DSM and Biotech Campus Delft .... E1
Start-up Village Partner ................. E2

8
1 4 1 4

F H
2 3 2 3

1 4 1 4

G I
2 3 2 3

F H
BGene .............................................. F1 Cellulosic Technologies UG .......... H1
Evonetix Ltd .................................... F2 LignoPure GbR .............................. H2
FGen GmbH .................................... F3 Indianes ......................................... H3
Abolis Biotechnologies .................. F4 ScobyTec ....................................... H4

G I
EBS – Engineering BioSurfactants G1 Innovived VZW ................................ I1
Syngulon SA .................................. G2 Senbis Polymer Innovations B.V ... I2
Chrysalix Technologies Ltd .......... G3 NEFFA .............................................. I3
Fornia BioSolutions Inc. ................ G4 Vienna Textile Lab ........................... I4

9
Start-up Profiles
Abolis Biotechnologies

Founded: 2014
Number of Employees: 25
Country: France
Investors: –
Active in: chemistry, cosmetics, pharmaceuticals, nutraceutic
Website: http://abolis.fr/

Which input does your business/core technology provide towards a bio-based economy?
Abolis Biotechnologies added value is to develop ecofriendly bio-processes for the pro-
duction of highly complex chemical molecules using synthetic biology. We are specialized
on yeast genetic engineering, focusing on the development of very long synthetic path-
ways, in order to improve and fasten industrial fermentation processes for many customer
products.

Which market/clients do you address and which short-term/long-term goals do you have?
Abolis Biotechnologies supports customers in their ambition to reduce their dependence
on fossil carbon and toxic chemicals and decrease waste.

What makes your approach unique compared to other stakeholders in the field?
Abolis Biotechnologies makes a difference by leveraging our genetic tools, proprietary
AI-based design software, micro-organism robotic assembly line, cutting-edge analytical
science and advanced fermentation technologies to produce identical or equivalent mole-
cules to the ones used today. From white paper to “yeast’s factory”, we work in partnership
with our customers and co-partners, to provide an economically and technically efficient
industrial process.

CONTACT

A. Molina (VP Industrial Partnerships)


alain.molina@ammolina.fr · +33-783317901

11
aquila biolabs GmbH

Founded: 2014
Number of Employees: 11
Country: Germany
Investors: –
Active in: laboratory devices, bioprocessing, biotechnology, fermentation
Website: https://aquila-biolabs.de

Which input does your business/core technology provide towards a bio-based economy?
aquila biolabs focuses on the development of innovative laboratory devices. Together
with leading scientists, aquila biolabs systematically identifies challenges in the area of
bioprocessing, evaluates respective solutions and turns them into marketable products.
Thereby, the company contributes to the digitization of bioprocessing and hence the real-
ization of a global bioeconomy.

Which market/clients do you address and which short-term/long-term goals do you have?
Nowadays, researchers in both academia and industry perform countless shake flask fer-
mentations. To them aquila biolabs offers technologies for non-invasive biomass moni-
toring (CGQ) and automated feeding of liquids (LIS), adding a new level of bioprocess
understanding and control. In the long-term, aquila biolabs’ vision is to act as an enabler
for Industry 4.0 applications in bioprocessing.

What makes your approach unique compared to other stakeholders in the field?
As the first smart sensor for non-invasive online monitoring of biomass, the CGQ elimi-
nates the need for manual biomass measurements in shaken as well as stirred systems.
The LIS technology allows for automated feeding experiments and enables users to take
their shake flask fermentations to the next level. Thus, aquila biolabs provides the tools for
smart bioprocess development in shake flasks.

CONTACT

Jens Bayer (Marketing & Sales Director)


info@aquila-biolabs.de · +49-163-2922615

12
BGene

Founded: 2014
Number of Employees: 15
Country: France
Investors: –
Active in: cosmetics, flavours, fragrances
Website: https://bgene-genetics.com/

Which input does your business/core technology provide towards a bio-based economy?
BGene develops the sustainable bio-production of high-value added molecules from abun-
dant, renewable and non-food raw materials using synthetic biology and microbial biodi-
versity. BGene microbial chassis are in silico designed, robotically constructed to become
eco-friendly micro-factories, with the mission to replace petro-sourced or intensive culture
processes.

Which market/clients do you address and which short-term/long-term goals do you have?
BGene addresses actors in the sector of flavors and fragrances, willing to shift to envi-
ronmentally friendly production modes. We design new bioproduction processes for their
own molecules, and we also develop our Proprietary Ingredients for this market. In the
foreseeable future, the synthesis of these natural molecules will be demonstrated at an
industrial scale, from renewable carbon sources.

What makes your approach unique compared to other stakeholders in the field?
BGene develops cutting-edge technologies integrating computer science, biology and fer-
mentation. We can explore data bases to find biological pathways for the synthesis of a
molecule, select for a pre-wired microbial chassis, metabolically model it and thus con-
struct a cloning plan. The strains are then robotically constructed and tested in bioreac-
tors in a rational and cost-effective manner.

CONTACT

Alexia Chandor (Chief R&D Officer)


alexia.chandor@bgene-genetics.com · +33 4 56 52 08 76

13
Bialtec SAS

Founded: 2012
Number of Employees: 9
Country: Colombia
Investors: 3
Active in: feed additives, pet food
Website: https://bialtec.co/

Which input does your business/core technology provide towards a bio-based economy?
All the additives we produce are made by biotechnology. Furthermore, we perform intesti-
nal microbiota DNA sequences and inhibition tests to develop our formulations. We also
develop a simulator of the gastrointestinal system that allows us to predict changes as-
sociated with diets, additives, pathogens, antibiotics and others. We want to understand
the animal intestinal microbiota in order to create the best additives.

Which market/clients do you address and which short-term/long-term goals do you have?
Feed producer that use our additives can assist in the reduction of antibiotic growth pro-
moters. Our goal is to establish ourselves in Europe and continue designing the gastroin-
testinal system simulator with real data collected by DNA sequencing, to continue creat-
ing the next generation of animal growth promoters free of antibiotics.

What makes your approach unique compared to other stakeholders in the field?
Metagenomic data helps us to design better products and measure their impact, we also
design performance simulations under certain conditions. We have developed an encap-
sulation, a protection against thermal and digestive processes for live strains used in our
products. We can also protect phytobiotics and other temperature sensitive molecules.

CONTACT

Mauricio Agudelo (CEO)


mauricio.agudelo@bialtec.co · +57-3013716979

14
Bicomer

To be Founded: 2020
Number of Employees: 2
Country: Germany
Investors: –
Active in: biotechnology, cosmetics, feed
Website: https://www.bicomer.de/

Which input does your business/core technology provide towards a bio-based economy?
Bicomer offers a new solution for the production of natural astaxanthin. We use renew-
able substrates in a microbial fermentation to produce astaxanthin. Our microorganism
Corynebacterium glutamicum is used since over 60 years for safe production of amino
acids in the food and feed market. We further develop the platform technology for produc-
tion of high performance carotenoids.

Which market/clients do you address and which short-term/long-term goals do you have?
We offer natural astaxanthin as antioxidant for the cosmetics industry. Moreover, astax-
anthin is used as a colorant in the feed industry for coloration of fish and other animal
based products. Our natural product is different from the algae-based astaxanthin as it is
the free form astaxanthin. On the long-term, we want to offer natural astaxanthin that was
developed and produced exclusively in Europe.

What makes your approach unique compared to other stakeholders in the field?
Bicomer offers astaxanthin in its free form in comparison to algal-based products. More-
over, we developed a coproduction approach: two high-value feed supplements; astaxan-
thin and lysine, are produced within one fermentation, thus adding value to the astaxanthin
product as the essential amino acid lysine is an add-on. Moreover, Bicomer has developed
other novel innovative carotenoid products.

CONTACT

Nadja Alina Henke (CEO)


n.henke@uni-bielefeld.de · +49-521-106 5604

15
Cellulosic Technologies UG

Founded: 2019
Number of Employees: 3
Country: Germany
Investors: –
Active in: personal care, home care and food & beverages
Website: https://www.cellulosictechnologies.com/

Which input does your business/core technology provide towards a bio-based economy?
We are an industrial biotech company specializing in bacterial cellulose production and its
applications, mainly as sensory materials and rheology modifiers.

Which market/clients do you address and which short-term/long-term goals do you have?
We are active in the market of personal & home care as well as food & beverages. As a
short-term goal, we are introducing a sensory material which is a biodegradable and sus-
tainable bio-based material, an alternative to plastic microbeads as well as liquid plastic
(acrylates) in personal and home care applications. As a long term goal, this material has
an application as a rheology modifier mainly in food, paint and coatings applications.

What makes your approach unique compared to other stakeholders in the field?
Our value proposition is sustainable, toxic and waste-free cellulose technology using mi-
crobiology and biomaterial science. We also have the competence to modify the chemical
and physical properties based on application. Our microbial cellulose production process
is patent protected.

CONTACT

Srinivas Karuturi (Managing Director)


contact@cellulosictechnologies.com · +49-15211217539

16
Chrysalix Technologies Ltd

Founded: 2017
Number of Employees: 4
Country: United Kingdom
Investors: –
Active in: biorefining
Website: http://www.chrysalixtechnologies.com/

Which input does your business/core technology provide towards a bio-based economy?
We provide a chemical process that uses unwanted waste, wood and agricultural residues
to produce high-quality cellulose, lignin and by-products (e.g. furfural, acetic acid). Com-
pared to other pulping technologies, we offer a significant reduction in capital costs and
lower energy requirements, resulting in better profit margins and making bio-refining more
competitive with the traditional petrol-based industry.

Which market/clients do you address and which short-term/long-term goals do you have?
We are addressing the bio-refining market, specifically companies with an abundance of
underused biomass resources and a use for a new source of cellulose. Our short-term
goal is to build a pilot plant that can supply small quantities of cellulose and lignin to
start product development. Our long-term goal is to be able to offer a technology package
for biorefiners across the planet, using a variety of input materials and producing a large
portfolio of products.

What makes your approach unique compared to other stakeholders in the field?
Our proprietary process uses a low-cost ionic solvent which offers a significant reduc-
tion in capital cost and energy requirements compared to traditional pulping technologies.
Combined with the ability to work with various waste products, e.g. sawdust, sugarcane
bagasse, demolition waste, and wood, we can offer very attractive returns on investment
and relatively small scales, reducing the need for large capital investments.

CONTACT

Florence Gschwend (CEO)


florence@chrysalixtechnologies.com · +44-7946489297

17
dieWurmfarm

Founded: 2017
Number of Employees: 4
Country: Austria
Investors: 1
Active in: insect-based food and feed, insect farming
Website: https://www.diewurmfarm.at/

Which input does your business/core technology provide towards a bio-based economy?
Insect production is an innovation in agriculture and is particularly challenging in the or-
ganic sector. By implementing regional insect production, food surpluses and sidestreams
can be processed into valuable new foods, avoiding food waste. Furthermore, vacant ag-
ricultural buildings will find new use and the lack of protein in human food and feed for
chickens and fishes can be compensated in future with sustainable insect production.

Which market/clients do you address and which short-term/long-term goals do you have?
As an ecologically produced sources of protein, our insect products are in high demand
in the current and future market. Our target consumers are open-minded, environmen-
tally conscious, health-conscious and curious. The overall goal is to create a new market
segment using regional food side streams to produce sustainable insect-based foods.
Smaller goals include the approval of insect excrement as a fertilizer, development and
automation of the insect production.

What makes your approach unique compared to other stakeholders in the field?
We are the first organic insect breeder in austria, do our own research on insect farming
technologies and further processing. Our best-seller are roasted, spicy mealworm fed with
chili cut offs and our very fine mealworm powder.

CONTACT

Andreas Koitz (CEO)


andreas.koitz@diewurmfarm.at · +43-6641904409

18
EBS – Engineering BioSurfactants

To be Founded: 2020/2021
Number of Employees: 3
Country: Germany
Investors: –
Active in: biosurfactants, e.g. for the cosmetics market

Which input does your business/core technology provide towards a bio-based economy?
EBS is a process engineering company that produces biosurfactants from sustainable
substrates with its own designed fermentation process. This could provide the means to-
wards a biobased surfactant market. EBS develops production and purification processes
for surfactants that are produced by microorganisms using sugars and vegetable oils.

Which market/clients do you address and which short-term/long-term goals do you have?
Upon initiation, EBS will target cosmetics producers, providing them with completely natu-
ral alternatives to the surfactants they currently use. Later on, EBS will expand to the larger
detergent market. Our vision is to provide our customers with high-end products offering
more-than-satisfactory performance while simultaneously not affecting the environment
negatively in any possible way.

What makes your approach unique compared to other stakeholders in the field?
Current biosurfactants used in the market do not cover all the structural variety needed.
Our proposed surfactants can fill this market gap. Together with our sustainable produc-
tion process using wildtype, non-pathogenic microorganisms, these antimicrobial surfac-
tants have the competitive advantage needed for a profitable industrial production.

CONTACT

Amira Oraby (CEO)


Amira.oraby@igb.fraunhofer.de · +4917670559188

19
Evonetix Ltd

Founded: 2015
Number of Employees: 39
Country: United Kingdom
Investors: –
Active in: laboratory devices, synthetic biology for academia,agbio, pharma and industry
Website: https://www.evonetix.com/

Which input does your business/core technology provide towards a bio-based economy?
We aim to sell an enabling technology to every lab, enabling the acceleration of synthetic
biology applications globally and the generation of enabled products. These applications
will address some of the worlds biggest problems that require a biological approach. We
aim to sell the instrument and proprietary consumables to end users.

Which market/clients do you address and which short-term/long-term goals do you have?
Our long-term goal is to have one of our platforms on every lab bench as DNA synthesis
underpins many applications. We can serve a diverse audience of customers including
academia, agbio, pharma and industry. In the meantime, we are aiming to connect with
potential users of the technology to understand the product attributes required for each of
the different customer segments and to build a platform that addresses the current unmet
needs in the synthetic biology market as a whole.

What makes your approach unique compared to other stakeholders in the field?
We are developing a bench top DNA synthesizer which will accelerate the rate of rapid
prototyping required to unlock the potential of bioengineering to tackle problems including
renewable and sustainable biofuels, feeding the growing population, materials using re-
newable feedstocks and medicines. We have developed a unique solution that combines
thermal control in a highly parallel format to enable the precise synthesis and assembly
of long high fidelity DNA at scale in a rapid turnaround time. This enables customers to
create whole pathways of highly diverse combinatorial libraries to shortcut the process of
screening for highly desirable proteins.

CONTACT

Stephanie Brooking (Head of Product Development)


stephanie.brooking@evonetix.com · +44-7445691309

20
FGen GmbH

Founded: 2011
Number of Employees: 10
Country: Switzerland
Investors: –
Active in: bio-based chemicals, food and nutrition, feed, agriculture
Website: http://fgen.ch/

Which input does your business/core technology provide towards a bio-based economy?
FGen develops and optimizes microbial strains (bacteria, yeasts and fungi) by combining
biological engineering, such as synthetic biology or non-GMO methods, with a proprietary
high-throughput screening platform. The constructed microbes find application in bio-
based production, in the food and feed sector, in agriculture or are used as probiotics.

Which market/clients do you address and which short-term/long-term goals do you have?
FGen collaborates as contract research organization with partners from industrial biotech,
life sciences and pharma, and has a successful track record in industrial strain develop-
ment and improvement. The main goals of the company are to enlarge its service activi-
ties and in the medium term to develop proprietary microbes for specific applications.

What makes your approach unique compared to other stakeholders in the field?
FGen has developed and commercialized the nanoliter-reactor screening platform that
enables the analysis of cell libraries at rates of up to 1 million clones per day under biopro-
cess and application relevant conditions. The technology therefore not only surpasses the
throughput of current methods by orders of magnitude but also ensures that strain traits
are maintained during scale-up and production.

CONTACT

Andreas Meyer (CEO)


meyer@fgen.ch · +41-61-6332920

21
Fornia BioSolutions Inc.

Founded: 2015
Number of Employees: 15
Country: United States
Investors: Hong Kong based private investment company
Active in: AI-based bioprocesses & fermentation, for biotech industry & biopharma
Website: https://forniabiosolutions.com

Which input does your business/core technology provide towards a bio-based economy?
Fornia’s core technology is an integrated platform, a “one-stop shop” encompassing gene
discovering to commercialization of products. Our focus is market profitability driven and our
aim is to launch superior microbial products that betters everyday life in the most environ-
mentally friendly way possible. Fornia has always focused on implementing and improvising
green chemistry and bio-based recycling in all its R & D work and future product lines.

Which market/clients do you address and which short-term/long-term goals do you have?
Our AI-guided biobased product development platform (AIGBD) is extremely robust and
has broad application. We offer both AI-guided protein engineering as well as strain devel-
opment services to clients from bio-industrial, bio-pharma and environmental sectors of
biotech. Our short-term goal is to work with broad spread of clients to improve their com-
mercial pipeline. Our long-term goal is to have our own product pipeline, developed using
our advanced technology.

What makes your approach unique compared to other stakeholders in the field?
We provide an integrated platform from gene discovery to commercialization of products.
Fornia’s AIGBD platform is disrupting existing technologies today, as it exploits AI with
extreme creativity, and in ways that has never explored or studied before in the area of
synthetic biology. The results of our cutting-edge AIGBD platform are faster commercial-
ization, significantly better profit margins for clients, and superior bio-products compared
to existing market.

CONTACT

Goutamie Banerjee (Co-founder and Director)


goutami.banerjee@forniabiosolutions.com · +1-510-264-0183

22
GREEN ROSE
Green Rose Chemistry CHEMISTRY

Founded: 2019
Number of Employees: 1
Country: United Kingdom
Investors: –
Active in: solvents, paints and coatings, adhesives, printing inks
Website: https://www.greenrosechemistry.com

Which input does your business/core technology provide towards a bio-based economy?
Green Rose Chemistry helps companies transition from harmful petroleum-based solvents
to safe, bio-based alternatives. We use our scientific expertise to take the guesswork out
of solvent substitution, accelerating and de-risking adoption of bio-based solvents. Green
Rose empowers industry to make the right solvent choices, maintaining product perfor-
mance while stepping into the bio-economy.

Which market/clients do you address and which short-term/long-term goals do you have?
We are equipped to help any client that uses solvents in their products/processes, whether
it’s a short bit of advice or a long-term research project. Paints/coatings, adhesives, and
printing inks are our initial targets due to strong drivers in these markets, but our solvent
science can easily be applied in any field. We hope to complete 3-5 client projects in our
first year, and in the long term become the EU’s top solvent consultancy.

What makes your approach unique compared to other stakeholders in the field?
Green Rose Chemistry is a team of experts in solvents and chemical regulation, with over
40 years combined experience in applying chemistry to meet industrial needs. Our ex-
pertise in the chemistry of green solvents enables us to provide tailored advice and R&D
services that solve specific issues and avoid regrettable substitutions. Green Rose demys-
tifies the complex science of solvents, empowering industry to go green.

CONTACT

Anna Zhenova (Founder & CEO)


anna@greenrosechemistry.com

23
Higher Steaks

Founded: 2018
Number of Employees: 5
Country: United Kingdom
Investors: –
Active in: cell-based meat
Website: https://www.highersteaks.com/

Which input does your business/core technology provide towards a bio-based economy?
Higher Steaks is a cell-based meat company that creates meat using cell culture tech-
niques. We are focused on pork and have unique technologies that will get a safer, tastier
and cost efficient product to industrial scale. Higher Steaks was backed by the Pearse
Lyons accelerator, a late stage ag tech accelerator, and has been mentioned by Forbes,
Sifted, Agfunder and more. Our founding team and advisory board consists of world lead-
ing engineers, scientist and repeat entrepreneurs.

What makes your approach unique compared to other stakeholders in the field?
We have a unique technologies that allow us to overcome the biggest challenges in the
industry and make cell-based meat a reality. Using state-of-the-art cell culture techniques,
a small sample of cells from an animal will be expanded by feeding these cells a rich and
animal free growth media. When these cells have grown we can then use different meth-
ods in order to form the desired meat product.

CONTACT

Benjamina Bollag (CEO & Co-founder)


benjamina@highersteaks.com

24
Indianes

Founded: 2017
Number of Employees: 3
Country: Spain
Investors: –
Active in: footware, innovative materials
Website: https://www.indianesfootwear.com

Which input does your business/core technology provide towards a bio-based economy?
Our model is based on a circular economy, where from the recovery of an agricultural
waste generated in the banana industry, through collaboration with native communities
of the Colombian region, a fiber is extracted from the stem of the plant. This allows us to
generate fabrics and textile products (footwear) that adds to natural components, allows
to create biodegradable products more quickly, avoids the generation of durable garbage
and returns resources to the earth.

Which market/clients do you address and which short-term/long-term goals do you have?
In the short-term, we want to expand our commercialization to the USA, Canada and Eu-
rope. In the long term we aim for the Asian and South American market. In the future, we
want to sell banana fiber and fabric to other brands and producers.

What makes your approach unique compared to other stakeholders in the field?
Our product is the only shoe made of banana fiber and one of the few shoes completely
biodegradable. With this product, the community, technology, sustainability and design are
perfectly articulated. Furthermore, we are contributing to the development of Colombia,
especially the vulnerable community and the environment.

CONTACT

Ivan Rojas (CEO/R&D Product))


contact@indianesfootwear.com · +34-622-76 39 09

25
Innovived VZW

Founded: 2017
Number of Employees: 5
Country: Belgium
Investors: 3
Active in: 3D-printing
Website: www.innovived.com

Which input does your business/core technology provide towards a bio-based economy?
Innovived VZW is a student team within the Postgraduate Programme of Innovation and
Entrepreneurship of the KU Leuven. Our mission is to bring biology and technology to-
gether. We aim to establish and contribute to innovative projects within the 3D-printing
industry and to organize events that focus on knowledge transfer to future scientists. We
believe that by creating a bridge between biology and technology, applications with great
potential are made possible. The main focus of this year’s scientific project is to strive for
a sustainable way of 3D-printing, with zero waste and the reusage of waste streams.

Which market/clients do you address and which short-term/long-term goals do you have?
We are a student-team. Currently, we are looking for potential partners that can back us
in our project to push forward our business idea. For instance, in one project we use ciga-
rette butts as resource for new products. It is one of the most found plastics in the seas
and oceans and has become an enormous problem. We try to purify these filters biochemi-
cally and treat them with plasticizer to give these filters a second life in a 3D-printing ap-
plication.

What makes your approach unique compared to other stakeholders in the field?
We have the aim to combine 3D-printing with biotechnology to develop sustainable prod-
ucts. Because we are a students, we have a constant input of new members with new
ideas, which results in new and interesting ideas.

CONTACT

Joris Kenis (Team Leader)


joris.kenis@innovived.com · +32-473417355

26
Kapsera SAS

Founded: 2018
Number of Employees: 7
Country: France
Investors: Demeter
Active in: agriculture , biotechnology
Website: www.kapsera.com

Which input does your business/core technology provide towards a bio-based economy?
Kapsera proposes an innovative bio-formulation for microbials product. We develop a new
kind of alginate microcapsules for agricultural applications. Our aim is to improve field
performance of microbial biofertilizers and biopesticides thanks to our technology. This
way we contribute to the development of a sustainable and productive agriculture.

Which market/clients do you address and which short-term/long-term goals do you have?
In the short-term, Kapsera develops products based on its technology through partner-
ship with leading business companies in agriculture. In the long term, Kapsera will operate
as producer to sell the final product to marketers. Our first bioencapsulated product is
currently under development and will be available by 2022.

What makes your approach unique compared to other stakeholders in the field?
Kapsera’s uniqueness resides in our bio-compatible and sustainable technology that per-
fectly fits to the microbes’ needs. Our bio-based microcapsules are designed for enhancing
the survival and the efficiency of living beneficial microbes. By understanding microbes,
and using sustainable alginate, Kapsera paves the road to a real bio-formulation.

CONTACT

Marie Tranier (Project Manager)


marie.tranier@kapsera.com · +33-630893147

27
Knufmann GmbH

Founded: 2010
Number of Employees: 18
Country: Germany
Investors: –
Active in: algea based food, power foods
Website: www.pureraw.de

Which input does your business/core technology provide towards a bio-based economy?
We are specialists in the use of bio-alge in our products and create a sustained base for
the food market.

Which market/clients do you address and which short-term/long-term goals do you have?
We address a broad customer base, as our products are for everyone who is looking for
organic, vegan and raw alternatives.

What makes your approach unique compared to other stakeholders in the field?
The algae for our products are directly produced in Germany.

CONTACT

Dominik Laux (PR agent)


dominik@laux-prdepartment.com · +49-1573-1733223

28
LignoPure GbR

Founded: 2019
Number of Employees: 4
Country: Germany
Investors: –
Active in: biopolymers & materials (short-term), Food & Cosmetics (long-term)
Website: https://lignopure.de

Which input does your business/core technology provide towards a bio-based economy?
In LignoPure we provide a natural biopolymer – Lignin. Already available in industrial scale
as a side stream from biorefineries, LignoPure is able to tailor lignin for specific applica-
tions, e.g. as a replacement for conventional oil-based polymers/plastics. Thereby lignin
is not only seen as a cheap and green filler but as a multifunctional biopolymer which can
act as an UV-protector and many more.

Which market/clients do you address and which short-term/long-term goals do you have?
Starting our business in 2019, we target the material market with three products: porous
materials (pu-foams for insulation), lignin-composites (adhesive tapes) and vegan leather.
To increase the awareness of lignin, we offer feasability studies and product development
for biorefineries and B2C companies. Our long-term goal is to address food and cosmetic
markets in form of texturizers and microbeads.

What makes your approach unique compared to other stakeholders in the field?
Compared to our competitors, we don’t focus on the breakdown of lignin into its building
blocks, but use it in a natural form, combining biorefineries with B2C companies. With our
protected technology and our know-how, we are able to tailor lignin for specific applica-
tions, enhancing the multifunctional properties lignin has to offer.

CONTACT

Stefan Boersting (Process and Product Developer)


stefan.boersting@lignopure.de · +49-176-72171540

29
madebymade GmbH

Founded: 2017
Number of Employees: 6
Country: Germany
Investors: –
Active in: insect based feed, insect farming
Website: www.madebymade.eu

Which input does your business/core technology provide towards a bio-based economy?
We supply three crucial components for a bio-based economy. We contribute to the dis-
posal of organic residues by feeding them to insects in order to improve the circular econ-
omy. We produce high-quality and sustainably produced animal proteins and fats for the
animal feed industry and supply high-quality and sustainably produced soil improvement
substrate.

Which market/clients do you address and which short-term/long-term goals do you have?
Our customers are protein traders, companies with organic residues, organic farmers, the
feed industry and aquacultures. Our short-term goal is to start the first industrial plant for
insect protein near Leipzig in 2020. In five years, we want to scale to four plants in three
countries. Our long-term goal is to scale to 30 modular plants with 30 million profit in ten
years.

What makes your approach unique compared to other stakeholders in the field?
Our modular system and the type of insect we use enable us to produce where organic
residues accumulate. We have developed a system that can be set up and operated world-
wide without specific adaptations. In addition, the plant size can easily be adapted to the
available space, without planning costs or changes to the system being necessary.

CONTACT

Kai Hempel (CEO)


kai.hempel@madebymade.eu · +49-152-54502505

30
MilliDrop

Founded: 2015
Number of Employees: 9
Country: France
Investors: Quadrivium I (Seventure Partners)
Active in: laboratory devices, life science research
Website: www.millidrop.com

Which input does your business/core technology provide towards a bio-based economy?
MilliDrop develops enabling technologies for the bio-based economy. Its droplet-based
millifluidics technology brings high-throughput at lower cost per assay. This will lead to a
better knowledge of microorganisms and faster time to produce.

Which market/clients do you address and which short-term/long-term goals do you have?
MilliDrop provides its disruptive solutions to academic laboratories and corporates de-
veloping bio-based products for agriculture, food & feed, chemistry and healthcare.
MilliDrop aims to launch its second instrument by early-2021 to reach an installed base of
400 machines by 2024.

What makes your approach unique compared to other stakeholders in the field?
MilliDrop technology enables to miniaturize samples and automate fluidic processes. As
a consequence, the full microbiology workflow (isolation, culture, measurement) can be
integrated in a benchtop instrument. Thousands of experiments can be carried out simul-
taneously, for a fraction of the price it would cost with standard methods.

CONTACT

Laurent Boitard (COO & Co-Founder)


l.boitard@millidrop.com ) +33-6 64 34 23 94

31
Native Foods-Carrillo
Wilisch-Kreßner-GbR

Founded: 2019
Number of Employees: 2
Country: Germany
Investors: –
Active in: insect-based food
Website: www.native-foods.com

Which input does your business/core technology provide towards a bio-based economy?
Native Foods brings edible insects from farm to table. Currently, we develop and produce
insect snacks. They contribute to a healthy and sustainable diet and are the best door
opener to the world of entomophagy.

Which market/clients do you address and which short-term/long-term goals do you have?
In the short-term, we are planning to get into the retail with different solutions, mass prod-
ucts and products for specific target groups. We plan to be market leader in insect snacks
and bakery products.

What makes your approach unique compared to other stakeholders in the field?
Our expertise, business partners, high quality products, production facilities and efficiency
makes our approach unique.

CONTACT

Camilo Wilisch (Co-Founder)


camilo@native-foods.com · +49-176-23325742

32
NEFFA

Founded: 2008
Number of Employees: 2
Country: The Netherlands
Investors: –
Active in: fashion, innovative materials
Website: https://neffa.nl

Which input does your business/core technology provide towards a bio-based economy?
MycoTEX is based on the biological life cycle. Our shorter supply chain eliminates the
need for hazardous chemicals and pesticides. We reduce water usage by 99,5% and local
production is reducing transport. We only grow what we need and have no textile waste
during the production phase. And AFTER wearing, you can simply bury your garment in the
ground and it will naturally decompose.

Which market/clients do you address and which short-term/long-term goals do you have?
Our goal is to create innovative and sustainable fashion for ANY body. There are 7,7 billion
people on this planet that all need to be clothed. Many of us enjoy fashion and trends, but
the clothes that we get rid of are a big problem. For MycoTEX we went to the root of the
problem. MycoTEX creates sustainable fabric from mycelium, the roots of mushrooms.
With our 3D-modelling process we create seamless garments of this new textile that per-
fectly fit YOUR body without the need to cut and sew!

What makes your approach unique compared to other stakeholders in the field?
Unlike others MycoTEX is working on improving the WHOLE supply chain. Our competition
is either developing new materials based on current production techniques, which involves
extra steps and create a lot of waste. Or they are working on custom-fit production tech-
niques, which are not ready or ideal to wear from a material perspective. Our production
will be directly in 3D and therefore without leftover material or extensive handwork.

CONTACT

Aniela Hoitink (CEO & Founder)


aniela@neffa.nl · +31-627494040

33
Rebel Meat GmbH

Founded: 2019
Number of Employees: 3
Country: Austria
Investors: –
Active in: hybrid meat
Website: www.rebelmeat.com

Which input does your business/core technology provide towards a bio-based economy?
Rebel Meat creates hybrid meat products. We finished the development of a production
process that allows us to create hybrid meat products with the same sensory properties
as 100% meat, using only 50% of it. Currently, we are working on a 25% version. This will
reduces overall meat content and stet the stage for clean meat.

Which market/clients do you address and which short-term/long-term goals do you have?
We address the big market of flexitarians and environmentally conscious meat eaters. We
started sales to specialised burger restaurants in Austria and plan to be available Austria-
wide by the end of 2019. 2020, we plan to address the retail market in Austria and expand
to Switzerland. Product development: reduce meat content to 25%. Our long-term goal is
to introduce products with 25% clean meat.

What makes your approach unique compared to other stakeholders in the field?
Currently, there are no hybrid meat products available on the Austrian market. We adapted
our production method to equipment that is commonly found in meat- processing facili-
ties to make our technology easily scalable. The mushrooms emulate meat consistency
and we developed a process to fully eliminate the typical mushroom off-flavour. No artifi-
cial flavouring, colouring or other additives.

CONTACT

Cornelia Habacher (Head of Product)


cornelia.habacher@rebelmeat.com · +43-660-6889953

34
Roquette Klötze
GmbH & Co. KG

Founded: 2008
Country: Germany
Investors: –
Active in: algae cultivation, algae-based nutrition
Website: https://www.algomed.de/

Which input does your business/core technology provide towards a bio-based economy?
We’re pioneers in microalgae cultivation. 1999 saw the start of construction of Europe’s
largest micro-algae farm in Klötze, Germany. Just one year later, the first algae of the
species Chlorella vulgaris were cultivated in this farm, which is unique in the world. The
new and patented cultivation method was then seen as a “technological quantum leap in
the production of microalgae”. Until then, microalgae had mostly been produced in Asia
and America in open pond systems. The entire cultivation – from the first algae from our
master stock collection to the finished product – is done in Klötze, so it is entirely in our
own hands. It is also certified to international standards

What makes your approach unique compared to other stakeholders in the field?
Thanks to the many years of experience of our well-trained staff, the permanent checks
done by our in-house laboratory and the additional quality checks by external laboratories
and the authorities, we can ensure an exceptionally good level of quality for our products.
In addition, we are doing intensive research into continuous process optimization and new
possibilities for applying our products.

CONTACT

Jörg Ullmann (Managing Director)


+49 39 09 - 4 72 60

35
ScobyTec

Founded: 2014
Number of Employees: 3
Country: Germany
Investors: –
Active in: innovative material, automotive, footwear, fashion and apparel industries
Website: www.scobytec.com

Which input does your business/core technology provide towards a bio-based economy?
ScobyTec BNC technology is ready for industrial upscaling. With state-of-the-art realtime
sensing, tracking and automation methods over the complete product chain, and propri-
etary finishing methods we can guarantee homogene qualities and establish bio-fabrica-
tion standards that fit OEM supply chains.

Which market/clients do you address and which short-term/long-term goals do you have?
ScobyTec addresses automotive, shoe, fashion and apparell industries as well as elec-
tronic components manufactures. With our platform material we are able to get significant
shares in our addressed markets. Short- term goal is the construction of a fully automated
pilot plant which can satisfy existing customer inquiries and demonstrate industrial scal-
ing.

What makes your approach unique compared to other stakeholders in the field?
ScobyTec BNC is a true biofabricated sustainable platform material. ScobyTec has devel-
oped an industrially scalable process and finishing methods which achieve extraordinary
qualities suitable for automotive industries.

CONTACT

Bernhard Schipper (Products & Marketing)


bernhard.schipper@scobytec.com · +49-176-21011388

36
Senbis Polymer
Innovations B.V.

Founded: 2017
Number of Employees: 10
Country: The Netherlands
Investors: –
Active in: R&D of (bio)polymers for several industries
Website: https://senbis.com

Which input does your business/core technology provide towards a bio-based economy?
Senbis is a company that offers R&D services to the polymer industry, in which there has
been a strong focus on biopolymers in recent years. Additionally, Senbis develops its own
sustainable products. These products are either compostable or biodegradable. This year
Senbis has launched a compostable PLA yarn as well as a compostable horticulture rope.
Currently, Senbis is implementing a test-field with soil-degradable grass infill for sports
fields. Other developments are a marine degradable rope for the fishing industry, a marine
degradable mussel net and a soil-degradable trimmer line.

Which market/clients do you address and which short-term/long-term goals do you have?
Any customer that is developing or using polymers in their applications is a potential cus-
tomer. Currently, we are working on building up the brand “Senbis Sustainable Products”.
The objective is to spin-off the brand as a separate production company so that Senbis
Polymer Innovations focus remains R&D while the production is handled by a standalone
subsidiary.

What makes your approach unique compared to other stakeholders in the field?
We are the only fully private R&D company in this field. Senbis took over the R&D equip-
ment of the company API. We have the unique advantage that we are not technology
dependent in our developments. Most manufactures develop new products based on the
production machinery they already possess, as our industry is very capital intensive. Sen-
bis looks for the best way of meeting market demands for a product and will find the right
production capacity afterwards via our very extensive network.

CONTACT

Gerard Nijhoving (Managing Director)


g.nijhoving@senbis.com · +31-591 69 2117

37
Syngulon SA

Founded: 2013
Number of Employees: 10
Country: Belgium
Investors: –
Active in: synthetic biology for industrial bioprocesses
Website: https://syngulon.com

Which input does your business/core technology provide towards a bio-based economy?
Syngulon develops antibiotic-free technologies for the use in so-called “micro-refineries”,
microbial cells that have been engineered to produce industrially relevant compounds.
These technologies incorporate bacteriocins into the biofermentation process by the se-
lection for the desired producing microbe and the prevention of contamination, by un-
desired mutants or external microbes. In both cases, clients using our systems for both
selection and prevention have observed an increase in product yield.

Which market/clients do you address and which short-term/long-term goals do you have?
We target any industrial process where microbial contamination is an important issue.

What makes your approach unique compared to other stakeholders in the field?
Our patented technologies are based on bacteriocins, ribosomally-produced peptides nat-
urally made by most bacteria to kill competitive microbial species. These bacteriocins can
have a limited or wide target range against other microbial species.

CONTACT

Guy Helin (CEO)


ghelin@syngulon.com · +32-475470708

38
Vienna Textile Lab

Founded: 2017
Number of Employees: 8
Country: Austria
Investors: –
Active in: textile dyes, white biotechnology
Website: www.viennatextilelab.at

Which input does your business/core technology provide towards a bio-based economy?
Vienna Textile Lab is a biotechnology company that produces dyes using naturally oc-
curring bacteria, providing the most sustainable, wholesome and environmentally friendly
alternative to conventional synthetic colours.

Which market/clients do you address and which short-term/long-term goals do you have?
Vienna Textile Lab addresses the market of textile, fashion and chemical industry. After a
stage of co-creation with designers, Vienna Textile Lab plans to sell yarns and textiles to
designers and fashion companies in the middle term, and then pure dyes to dye houses,
chemical companies and fibre/yarn producers in the long-term.

What makes your approach unique compared to other stakeholders in the field?
Vienna Textile Lab uniqueness is the use of natural occurring bacterial strains. Vienna
Textile Lab has surrounded itself with very strong partners – a research institute, a dye
house, a bacteria provider – and is also part of the Textiles Closing Busines Labs (TCBL)
network, a Horizon 2020 funded organisation.

CONTACT

Karin Fleck (CEO)


karin.fleck@viennatextilelab.at · +43-660-638 28 53

39
Whapow Deutschland GmbH

Founded: 2017
Number of Employees: 12
Country: Germany
Investors: –
Active in: algae-based food & beverages
Website: https://whapow.de/

Which input does your business/core technology provide towards a bio-based economy?
Our food & beverage applications seek to position micro-algae – the most resource ef-
ficient and nutrient dense naturally occurring food ingredient on earth – within the main-
stream of the food system.

Which market/clients do you address and which short-term/long-term goals do you have?
We target the “mindful consumer” in metropolitan areas everywhere. They find our prod-
ucts in corporate canteens, grab-n-go/convenience stores at work/play. In the short-term,
we seek to scale distribution for our frozen and freeze-dried snack products in selected
metropolitan areas and expand our product line-up and market reach in the long-term.

What makes your approach unique compared to other stakeholders in the field?
We are the first consumer-facing brand designed around the use of micro-algae as a key
ingredient for mainstream consumers. Our research efforts have already lead to the cre-
ation of two innovative product lines that did not exist previously: algae-based ice-cream
style snacks and freeze-dried algae-fruit blends.

CONTACT

Eskil Puhl (MD)


eskil@whapower.com · +49 179 49 16 537

40
Notes

41
Imprint

Publisher
BIOCOM AG
Lützowstr. 33–36
10785 Berlin
www.biocom.de

Layout
Benjamin Röbig
Michaela Reblin

Editorial Team
Ines Herlitze
Sandra Wirsching

Illustration
wowomnom/istockphoto.com

The profiles have been provided by the companies and organizations. BIOCOM makes no guarantee for the
content. The publication is available free of charge and part of the Start-up Village communication during
the “European Forum for Industrial Biotechnology and the Bioeconomy” to be held in Brussels, Belgium, 30
September–2 October 2019. The event is organised by EuropaBio with the support of BIOCOM AG and bio.be/
essenscia as local partner. (www.efibforum.com) All rights reserved.
www.efibforum.com

You might also like